Pathios Therapeutics

Pathios Therapeutics is a UK-based, clinical-stage biotech leveraging human genetics to develop first-in-class GPR65 inhibitors for cancer. The company's science centers on the acidic tumor microenvironment (TME), which activates GPR65 on immune cells like macrophages, T cells, and NK cells, driving them into a pro-tumorigenic state. By inhibiting GPR65, Pathios aims to reverse this immunosuppression at its root cause, potentially restoring anti-tumor immunity and enhancing the efficacy of existing immunotherapies. The company is advancing its lead oral candidate, PTT-4256, into clinical development for solid tumors.

Human genetics-led discovery platform focused on inhibiting the acid-sensing GPCR GPR65 to condition immune cells and reverse immunosuppression in the acidic tumor microenvironment.

Pathios is a pioneer in directly targeting GPR65, but faces broad competition from companies developing other TME-modulating and macrophage-reprogramming therapies. Its success depends on demonstrating superior or complementary efficacy to existing immunotherapies like checkpoint inhibitors.